Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00263 USD | +9.58% | 0.00% | -70.11% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Financials (USD)
Sales 2021 | 0.07 | Sales 2022 | 0.14 | Capitalization | 3.5M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -18M | EV / Sales 2021 | 112,421,804 x |
Net Debt 2021 | 7.1M | Net Debt 2022 | 7.15M | EV / Sales 2022 | 78,689,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 68.7% |
1 day | +9.58% | ||
Current month | -16.13% | ||
1 month | +13.04% | ||
3 months | -58.06% | ||
6 months | -80.00% | ||
Current year | -70.11% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Don Calabria
COO | Chief Operating Officer | 53 | - |
Steven Barnes
IRC | Investor Relations Contact | - | 14-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.00263 | +9.58% | 12 807 |
24-04-25 | 0.0024 | -4.00% | 100,000 |
24-04-24 | 0.0025 | 0.00% | 390,599 |
24-04-23 | 0.0025 | 0.00% | 153,000 |
24-04-22 | 0.0025 | -4.58% | 59,990 |
Delayed Quote OTC Markets, April 26, 2024 at 10:45 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-70.11% | 839K | |
-2.10% | 103B | |
+0.77% | 95.71B | |
+1.69% | 22.02B | |
-17.03% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-15.06% | 15.52B | |
+3.59% | 13.86B | |
+34.45% | 12.04B |
- Stock Market
- Equities
- ENDV Stock